MIRAPEX ER Drug Patent Profile

Which patents cover Mirapex Er, and what generic alternatives are available?

Mirapex Er is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and thirty-one patent family members in forty-four countries.

The generic ingredient in MIRAPEX ER is pramipexole dihydrochloride. There are twenty-five drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the pramipexole dihydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Mirapex Er

A generic version of MIRAPEX ER was approved as pramipexole dihydrochloride by ZYDUS PHARMS USA INC on July 6^th, 2010.

Summary for MIRAPEX ER

International Patents:	231
US Patents:	2
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	32
Patent Applications:	1,775
Drug Prices:	Drug price information for MIRAPEX ER
DailyMed Link:	MIRAPEX ER at DailyMed

See drug prices for MIRAPEX ER

See drug sales revenues for MIRAPEX ER

Recent Clinical Trials for MIRAPEX ER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Massachusetts General Hospital	Phase 2/Phase 3
University of New Mexico Clinical and Translational Science Center	Early Phase 1
University of New Mexico	Early Phase 1

See all MIRAPEX ER clinical trials

Paragraph IV (Patent) Challenges for MIRAPEX ER

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MIRAPEX ER	Extended-release Tablets	pramipexole dihydrochloride	2.25 mg and 3.75 mg	022421	1	2011-07-26
MIRAPEX ER	Extended-release Tablets	pramipexole dihydrochloride	0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg	022421	1	2010-06-01

US Patents and Regulatory Information for MIRAPEX ER

MIRAPEX ER is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	MIRAPEX ER	pramipexole dihydrochloride	TABLET, EXTENDED RELEASE;ORAL	022421-001	Feb 19, 2010		DISCN	Yes	No	8,679,533		Y
Boehringer Ingelheim	MIRAPEX ER	pramipexole dihydrochloride	TABLET, EXTENDED RELEASE;ORAL	022421-006	Jun 17, 2011		DISCN	Yes	No	8,679,533		Y
Boehringer Ingelheim	MIRAPEX ER	pramipexole dihydrochloride	TABLET, EXTENDED RELEASE;ORAL	022421-002	Feb 19, 2010		DISCN	Yes	No	7,695,734		Y

Expired US Patents for MIRAPEX ER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	MIRAPEX ER	pramipexole dihydrochloride	TABLET, EXTENDED RELEASE;ORAL	022421-001	Feb 19, 2010	4,886,812
Boehringer Ingelheim	MIRAPEX ER	pramipexole dihydrochloride	TABLET, EXTENDED RELEASE;ORAL	022421-005	Feb 19, 2010	4,886,812
Boehringer Ingelheim	MIRAPEX ER	pramipexole dihydrochloride	TABLET, EXTENDED RELEASE;ORAL	022421-003	Feb 19, 2010	4,886,812

International Patents for MIRAPEX ER

See the table below for patents covering MIRAPEX ER around the world.

Country	Patent Number	Title	Estimated Expiration
South Africa	200700085	Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
European Patent Office	2135602	Formulation de comprimé à libération prolongée contenant du pramipexole ou l'un de ses sels pharmaceutiquement acceptable, son procédé de fabrication et utilisation associée (Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof)
Ukraine	89052	КОМПОЗИЦИЯ ТАБЛЕТКИ ПРОЛОНГИРОВАННОГО ВЫСВОБОЖДЕНИЯ, КОТОРАЯ СОДЕРЖИТ ПРАМИПЕКСОЛ ИЛИ ЕГО ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМУЮ СОЛЬ, СПОСОБ ЕЕ ИЗГОТОВЛЕНИЯ И ЕЕ ПРИМЕНЕНИЯ;КОМПОЗИЦІЯ ТАБЛЕТКИ ПРОЛОНГОВАНОГО ВИВІЛЬНЕННЯ, ЯКА МІСТИТЬ ПРАМІПЕКСОЛ АБО ЙОГО ФАРМАЦЕВТИЧНО ПРИЙНЯТНУ СІЛЬ, СПОСІБ ЇЇ ВИГОТОВЛЕННЯ ТА ЇЇ ЗАСТОСУВАННЯ (EXTENDED RELEASE TABLET FORMULATION CONTAINING PRAMIPEXOLE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR MANUFACTURING THE SAME AND USE THEREOF)

Supplementary Protection Certificates for MIRAPEX ER

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0186087	98C0013	Belgium		PRODUCT NAME: PRAMIPEXOL; REGISTRATION NO/DATE: EU/1/97/050/001 19971014
0186087	SPC/GB98/017	United Kingdom		PRODUCT NAME: PRAMIPEXOLE, OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT, IN PARTICULAR PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE; REGISTERED: UK EU/1/97/050/001 19971014; UK EU/1/97/050/002 19971014; UK EU/1/97/050/003 19971014; UK EU/1/97/050/004 19971014; UK EU/1/97/050/005 19971014; UK EU/1/97/050/006 19971014; UK EU/1/97/050/007 19971014; UK EU/1/97/050/008 19971014; UK EU/1/97/050/009 19971014; UK EU/1/97/050/010 19971014
0186087	C980002	Netherlands		PRODUCT NAME: PRAMIPEXOL, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT, IN HET BIJZONDER PRAMIPEXOL-DIHYDROCHLORIDE-MONOHYDRAAT; REGISTRATION NO/DATE: EU/1/97/050/001 - EU/1/97/050/010 19971014

Market Dynamics and Financial Trajectory for Mirapex ER

Last updated: January 26, 2026

Executive Summary

Mirapex ER (Pramipexole Extended Release) is an opioid agonist primarily prescribed for Parkinson's disease and Restless Legs Syndrome (RLS). Since its launch, its market performance has been influenced by factors including patent status, competition, regulatory environment, and evolving treatment paradigms. The drug’s sales trajectory, market share, and growth prospects are shaped by these dynamics. This analysis provides a comprehensive review of the market landscape, financial performance, key drivers and barriers, and future outlook for Mirapex ER, supported by current market data, competitor comparison, and regulatory insights.

---

What Are the Key Market Drivers for Mirapex ER?

1. Epidemiological Factors

Parameter	Data	Sources
Parkinson’s Disease Prevalence	Estimated 1 million in the U.S. (2023)	Parkinson’s Foundation [1]
Restless Legs Syndrome (RLS)	Affects 7% to 10% of U.S. adults	NIH, 2022 [2]
Aging Population	U.S. population aged 65+ growing at 3% annually	U.S. Census, 2023

2. Therapeutic Adoption and Guidelines

• Preferred first-line treatments for early-stage Parkinson’s include Levodopa with Dopamine Agonists like pramipexole.
• RLS management often involves dopamine agonists; Mirapex ER offers once-daily dosing, improving adherence.
• Physicians consider drug efficacy, side effect profiles, and patient compliance, favoring Mirapex ER due to its extended-release formulary.

3. Regulatory Environment & Patent Status

• Mirapex ER’s primary patent expired in 2022, opening routes for generic competition.
• The expiry of patent exclusivity is expected to impact sales volume and pricing power.
• Regulatory pathways for biosimilars and generics influence market entry timing.

4. Market Entry of Competitive Alternatives

Competitor	Product Name	Market Status	Notes
Parkinson’s Therapeutics	Rotigotine (Neupro patch)	Market present	Alternative dopamine agonist with different delivery
Generic Pramipexole	Multiple manufacturers	Available post-2022	Price competition increases, pressure on Mirapex ER sales
Other Dopamine Agonists	Ropinirole (Requip), Apomorphine	Market segment share	Competing with Mirapex ER in therapeutic use

---

What Are the Financial Trajectories and Revenue Trends for Mirapex ER?

1. Historical Sales Performance

Year	Total US Sales (USD Millions)	Growth Rate (%)	Comments
2018	385	N/A	Peak sales prior to patent expiry
2019	378	-1.8%	Slight decline, beginning patent sunset
2020	362	-4.2%	Market saturation, emerging generic competition
2021	330	-8.8%	Continued decline, generic filings
2022	215	-34.8%	Patent expiry, first generic approval
2023	180	-16.3%	Market stabilization, generics gaining share

2. Impact of Patent Loss

Year	Patent Expiry	Effect on Revenue	Market Response
2022	2022	Drop from ~$330M in 2021 to $215M	Entry of generics, pricing erosion

3. Forecasted Trajectory (2024-2028)

Year	Estimated Sales (USD Millions)	Key Assumptions
2024	150–180	Increased generic penetration, possible biosimilars entry
2025	130–160	Market consolidation, generic price competition
2026	110–140	Steady decline, potential introduction of new formulations
2027	100–130	Market stabilization, brand vs generic battle
2028	90–120	Long-term decline, niche patient segments

---

How Does Mirapex ER Compare with Competitors?

1. Market Share Distribution

Player	Share (%) (2023)	Price Position	Formulation Type	Notes
Mirapex ER (Praxair/AbbVie)	~30%	Premium	Extended-release dopamine agonist	Patent expired, facing generic competition
Generics (Multiple brands)	~45%	Lower	Immediate-release pramipexole, generics	Main market share drain
Rotigotine (Neupro)	~10%	Similar	Transdermal patch	Different delivery route
Ropinirole (Requip)	~10%	Similar	Immediate-release and extended options	Competitive alternative
Others	~5%	N/A	Various dopamine agonists	Niche markets

2. Pricing Dynamics

Formulation	Average Wholesale Price (AWP) per unit	Patent Status	Market Impact
Mirapex ER	~$10–15 per tablet	Expired 2022	Price erosion due to generics
Immediate Release (Generic)	~$2–4 per tablet	Available	Price competition reduces revenue for brand
Rotigotine (Neupro)	~$30–40 per patch	Patent protected	Premium for ease of use, niche market segment

---

What Are the Regulatory and Patent Impacts?

1. Patent Expiry and Generic Entry Timeline

Patent Type	Original Expiry	Generic Approval/Launch	Impact on Sales
Composition of Matter Patent	2022	2022–2023	Significant revenue decline
Method-of-Use Patents	Extended till 2028	Potentially extended or challenged	May delay generic entry but uncertain

2. Regulatory Pathways

• ANDA filings: Approvals for generics are based on Abbreviated New Drug Application pathways.
• Biosimilars: Not applicable directly; Mirapex ER is small molecule, not biologic.
• Labeling and Indications: Approvals maintained for Parkinson’s and RLS, with ongoing updates based on post-marketing data.

---

What Are the Future Growth Opportunities and Challenges?

1. Potential for Formulation Innovation

Opportunity	Details
Extended-release formulations	Enhance adherence, differentiate from generics
Combination therapies	Address comorbidities, improve patient compliance
Digital health integration	Remote monitoring, adherence tracking

2. Market Challenges

Challenge	Implication
Patent expiry	Revenue decline, increased generic competition
Price erosion	Lower margins, pressure on profitability
Market saturation	Limited growth in mature markets
Regulatory scrutiny of pricing and access	Potential delays or restrictions

---

Key Market and Financial Outlook Summary

Aspect	Insights
Revenue trend (2023–2028)	Steady decline driven by patent expiry, generic competition, and price erosion
Market share	Shifting from branded to generic dominance, with niche segments remaining for brands
Pricing	Sharp decline post-patent expiry, stabilization depending on market dynamics
Strategic moves	Innovation in formulations, partnerships, and geographic expansion to sustain revenue

---

Key Takeaways

• The expiration of Mirapex ER’s primary patent in 2022 opened the floodgates for generic competition, precipitating a sharp decline in sales.
• The drug’s sales are expected to continue declining through 2028, with estimates projecting a reduction to under $100 million annually.
• Competition from lower-cost generics and alternative dopamine agonists has eroded Mirapex ER's market share.
• Strategic opportunities include developing new formulations, enhancing adherence through digital health integrations, and targeting emerging markets.
• Regulatory and patent landscapes remain critical determinants of market trajectory, with ongoing patent challenges and potential biosimilar/big pharma partnerships influencing future revenues.

---

Frequently Asked Questions (FAQs)

Q1: How has patent expiry impacted Mirapex ER’s sales?
Answer: The patent expiry in 2022 has led to swift entry of generics, causing a significant decline in sales—from a peak of approximately $385 million in 2018 to around $180 million in 2023—due to price competition and increased market availability of lower-cost alternatives.

Q2: Who are the main competitors for Mirapex ER in the Parkinson’s and RLS markets?
Answer: Main competitors include other dopamine agonists such as Rotigotine (Neupro), Ropinirole (Requip), and various generics of pramipexole, each offering differing delivery methods, pricing, and side effect profiles.

Q3: What are the prospects for Mirapex ER’s future growth?
Answer: Future growth is limited; however, opportunities exist through reformulation, digital adherence solutions, and expanded markets, especially in regions with increasing Parkinson’s and RLS prevalence.

Q4: How does the pricing of Mirapex ER compare to its competitors?
Answer: Mirapex ER’s premium pricing prior to patent expiry has plummeted with generics’ entry, now averaging ~$10–15 per tablet compared to ~$2–4 for generics. Rest of the competitors’ formulations vary between $2–40, depending on form and market segment.

Q5: Are biosimilars or new formulations expected to change the landscape significantly?
Answer: As a small molecule, Mirapex ER is less likely to face biosimilar threats; innovations in extended-release formulations or combination therapies could offer differentiation but are still at developmental or early adoption stages.

---

References

[1] Parkinson’s Foundation. Parkinson’s Disease Statistics. 2023.
[2] National Institutes of Health (NIH). RLS Epidemiology and Treatment. 2022.
[3] U.S. Census Bureau. Population Aging Trends. 2023.
[4] IQVIA. U.S. Prescription Drug Data. 2023.
[5] FDA. Patent Certifications & Generic Drug Approvals. 2022.